drugset
drugset / Trial / NCT00509691

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691 ↗

Phase 1 Completed 20 enrolled University of Louisville Penn State University · collab
NaSingle-groupOpen-labelSupportive care

Summary

RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have undergone a donor stem cell transplant and have cytomegalovirus infection that has not responded to therapy.

Timeline

Start
2007-06
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject cytomegalovirus pp65-specific cytotoxic T lymphocytes Cell therapy — Other

Indications

cancer